CoChat

Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis

Open access
Zhou, Ping-Ting, Li, Bo, Liu, Fu-Rao, Zhang, Mei-Chao, Wang, Qian, Li, Yan-Yan, Xu, Ci, Liu, Yuan-Hua, Yao, Yuan, Li, Dong · 2017 · Oncotarget
Cited by 70

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

// Ping-Ting Zhou 1, * , Bo Li 2, * , Fu-Rao Liu 1 , Mei-Chao Zhang 1 , Qian Wang 1 , Yan-Yan Li 1 , Ci Xu 1 , Yuan-Hua Liu 3 , Yuan Yao 4 , Dong Li 1 1 Department of Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China 2 Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China 3 Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China 4 Department of Radiation Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China * These authors have contributed equally to this work Correspondence to: Dong Li, email: lidong@shsmu.edu.cn Keywords: metformin, pancreatic cancer, diabetes, overall survival Received: August 29, 2016 Accepted: January 24, 2017 Published: February 25, 2017 ABSTRACT Background: Pancreatic cancer is a highly lethal disease with a poor prognosis while metformin has been associated with a decreased risk of pancreatic cancer. Although the benefit of metformin was observed for pancreatic cancer prevention, it is not clear whether it can also affect the survival of pancreatic cancer patients with type 2 diabetes mellitus. A systematic review and meta-analysis was conducted to assess the effect of metformin on the survival of pancreatic cancer patients with type 2 diabetes mellitus. Methods: Two independent authors searched PubMed and Web of science up to 08/07/2016. We assessed studies for eligibility, extracted data, and examined their quality, with the primary outcome as overall survival. We used published hazard ratio (HR) available or estimated based on other survival data. We pooled the data and used a random-effect model to combine direct comparisons from included articles. We also investigated treatment effects by different countries, quality and the time of metformin initiation. Results: We found that there was a relative survival benefit associated with metformin treatment compared with non-metformin treatment in both overall survival (OS) ([HR] 0.84; 95% confidence interval [CI]: 0.73 – 0.96). These associations were also observed in subgroups of Asian countries and high quality articles. Conclusions: Our results support the notion that metformin maybe the best anti-diabetic medicine of choice in patients with pancreatic cancer and concurrent type 2 diabetes mellitus. The perspectives of enhancing survival of pancreatic cancer patients with diabetes mellitus by the use of metformin deserve more attention in future research and clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15692

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 70

Metadata

Authors
Zhou, P.-T., Li, B., Liu, F.-R., Zhang, M.-C., Wang, Q., Li, Y.-Y., Xu, C., Liu, Y.-H., Yao, Y., & Li, D.
Venue
Oncotarget
Published
2017-02-25
Volume
8
Issue
15
Pages
25242-25250
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2589747936
Cited by
70
References
11
FWCI
0.72
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.